Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis

Sungchae Hong, Soohwan Yum, Hyun Jung Yoo, Sookjin Kang, Jeong Hyun Yoon, Dosik Min, Young Mi Kim, Yunjin Jung

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

For the purpose of development of orally active peptide therapeutics targeting NFκB for treatment of inflammatory bowel disease (IBD), two major barriers in oral delivery of therapeutic peptides, metabolic lability and tissue impermeability, were circumvented by introduction of a colon-targeted delivery system and cell permeable peptides (CPP) to NFκB inhibitory peptides (NIP). Suppression of NFκB activation was compared following treatment with various CPP conjugated NIPs (CPP-NIP). The most potent CPP-NIP was loaded in a capsule coated with a colon specific polymer, which was administered orally to colitic rats. The anti-inflammatory activity of the colon-targeted CPP-NIP was evaluated by measuring inflammatory indices in the inflamed colonic tissue. For confirmation of the local action of the CPP-NIP, the same experiment was done after rectal administration. Tissue permeability of the CPP-NIP was examined microscopically and spectrophotometrically using FITC-labeled CPP-NIP (CPP-NIP-FITC). NEMO binding domain peptide (NBD, TALDWSWLQTE) fused with a cell permeable peptide CTP (YGRRARRRARR), CTP-NBD, was most potent in inhibiting NFκB activity in cells. Colon-targeted CTP-NBD, but not colon-targeted NBD and CTP-NBD in an enteric capsule, ameliorated the colonic injury, which was in parallel with decrease in MPO activity and the levels of inflammatory mediators. Intracolonic treatment with CTP-NBD alleviated rat colitis and improved all the inflammatory indicators. CTP-NBD-FITC was detected at much greater level in the inflamed tissue than was NBD-FITC. Taken together, introduction of cell permeability and colon targetability to NIP may be a feasible strategy for an orally active peptide therapy for treatment of IBD.

Original languageEnglish
Pages (from-to)1310-1319
Number of pages10
JournalMolecular Pharmaceutics
Volume9
Issue number5
DOIs
Publication statusPublished - 2012 May 7

Fingerprint

Colitis
Colon
Peptides
Cytidine Triphosphate
Fluorescein-5-isothiocyanate
Inflammatory Bowel Diseases
Therapeutics
Capsules
Permeability
Rectal Administration

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Hong, Sungchae ; Yum, Soohwan ; Yoo, Hyun Jung ; Kang, Sookjin ; Yoon, Jeong Hyun ; Min, Dosik ; Kim, Young Mi ; Jung, Yunjin. / Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis. In: Molecular Pharmaceutics. 2012 ; Vol. 9, No. 5. pp. 1310-1319.
@article{f18d3bf0c0284ce4a94ed5c1497cb0ba,
title = "Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis",
abstract = "For the purpose of development of orally active peptide therapeutics targeting NFκB for treatment of inflammatory bowel disease (IBD), two major barriers in oral delivery of therapeutic peptides, metabolic lability and tissue impermeability, were circumvented by introduction of a colon-targeted delivery system and cell permeable peptides (CPP) to NFκB inhibitory peptides (NIP). Suppression of NFκB activation was compared following treatment with various CPP conjugated NIPs (CPP-NIP). The most potent CPP-NIP was loaded in a capsule coated with a colon specific polymer, which was administered orally to colitic rats. The anti-inflammatory activity of the colon-targeted CPP-NIP was evaluated by measuring inflammatory indices in the inflamed colonic tissue. For confirmation of the local action of the CPP-NIP, the same experiment was done after rectal administration. Tissue permeability of the CPP-NIP was examined microscopically and spectrophotometrically using FITC-labeled CPP-NIP (CPP-NIP-FITC). NEMO binding domain peptide (NBD, TALDWSWLQTE) fused with a cell permeable peptide CTP (YGRRARRRARR), CTP-NBD, was most potent in inhibiting NFκB activity in cells. Colon-targeted CTP-NBD, but not colon-targeted NBD and CTP-NBD in an enteric capsule, ameliorated the colonic injury, which was in parallel with decrease in MPO activity and the levels of inflammatory mediators. Intracolonic treatment with CTP-NBD alleviated rat colitis and improved all the inflammatory indicators. CTP-NBD-FITC was detected at much greater level in the inflamed tissue than was NBD-FITC. Taken together, introduction of cell permeability and colon targetability to NIP may be a feasible strategy for an orally active peptide therapy for treatment of IBD.",
author = "Sungchae Hong and Soohwan Yum and Yoo, {Hyun Jung} and Sookjin Kang and Yoon, {Jeong Hyun} and Dosik Min and Kim, {Young Mi} and Yunjin Jung",
year = "2012",
month = "5",
day = "7",
doi = "10.1021/mp200591q",
language = "English",
volume = "9",
pages = "1310--1319",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "5",

}

Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis. / Hong, Sungchae; Yum, Soohwan; Yoo, Hyun Jung; Kang, Sookjin; Yoon, Jeong Hyun; Min, Dosik; Kim, Young Mi; Jung, Yunjin.

In: Molecular Pharmaceutics, Vol. 9, No. 5, 07.05.2012, p. 1310-1319.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis

AU - Hong, Sungchae

AU - Yum, Soohwan

AU - Yoo, Hyun Jung

AU - Kang, Sookjin

AU - Yoon, Jeong Hyun

AU - Min, Dosik

AU - Kim, Young Mi

AU - Jung, Yunjin

PY - 2012/5/7

Y1 - 2012/5/7

N2 - For the purpose of development of orally active peptide therapeutics targeting NFκB for treatment of inflammatory bowel disease (IBD), two major barriers in oral delivery of therapeutic peptides, metabolic lability and tissue impermeability, were circumvented by introduction of a colon-targeted delivery system and cell permeable peptides (CPP) to NFκB inhibitory peptides (NIP). Suppression of NFκB activation was compared following treatment with various CPP conjugated NIPs (CPP-NIP). The most potent CPP-NIP was loaded in a capsule coated with a colon specific polymer, which was administered orally to colitic rats. The anti-inflammatory activity of the colon-targeted CPP-NIP was evaluated by measuring inflammatory indices in the inflamed colonic tissue. For confirmation of the local action of the CPP-NIP, the same experiment was done after rectal administration. Tissue permeability of the CPP-NIP was examined microscopically and spectrophotometrically using FITC-labeled CPP-NIP (CPP-NIP-FITC). NEMO binding domain peptide (NBD, TALDWSWLQTE) fused with a cell permeable peptide CTP (YGRRARRRARR), CTP-NBD, was most potent in inhibiting NFκB activity in cells. Colon-targeted CTP-NBD, but not colon-targeted NBD and CTP-NBD in an enteric capsule, ameliorated the colonic injury, which was in parallel with decrease in MPO activity and the levels of inflammatory mediators. Intracolonic treatment with CTP-NBD alleviated rat colitis and improved all the inflammatory indicators. CTP-NBD-FITC was detected at much greater level in the inflamed tissue than was NBD-FITC. Taken together, introduction of cell permeability and colon targetability to NIP may be a feasible strategy for an orally active peptide therapy for treatment of IBD.

AB - For the purpose of development of orally active peptide therapeutics targeting NFκB for treatment of inflammatory bowel disease (IBD), two major barriers in oral delivery of therapeutic peptides, metabolic lability and tissue impermeability, were circumvented by introduction of a colon-targeted delivery system and cell permeable peptides (CPP) to NFκB inhibitory peptides (NIP). Suppression of NFκB activation was compared following treatment with various CPP conjugated NIPs (CPP-NIP). The most potent CPP-NIP was loaded in a capsule coated with a colon specific polymer, which was administered orally to colitic rats. The anti-inflammatory activity of the colon-targeted CPP-NIP was evaluated by measuring inflammatory indices in the inflamed colonic tissue. For confirmation of the local action of the CPP-NIP, the same experiment was done after rectal administration. Tissue permeability of the CPP-NIP was examined microscopically and spectrophotometrically using FITC-labeled CPP-NIP (CPP-NIP-FITC). NEMO binding domain peptide (NBD, TALDWSWLQTE) fused with a cell permeable peptide CTP (YGRRARRRARR), CTP-NBD, was most potent in inhibiting NFκB activity in cells. Colon-targeted CTP-NBD, but not colon-targeted NBD and CTP-NBD in an enteric capsule, ameliorated the colonic injury, which was in parallel with decrease in MPO activity and the levels of inflammatory mediators. Intracolonic treatment with CTP-NBD alleviated rat colitis and improved all the inflammatory indicators. CTP-NBD-FITC was detected at much greater level in the inflamed tissue than was NBD-FITC. Taken together, introduction of cell permeability and colon targetability to NIP may be a feasible strategy for an orally active peptide therapy for treatment of IBD.

UR - http://www.scopus.com/inward/record.url?scp=84860720700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860720700&partnerID=8YFLogxK

U2 - 10.1021/mp200591q

DO - 10.1021/mp200591q

M3 - Article

C2 - 22428658

AN - SCOPUS:84860720700

VL - 9

SP - 1310

EP - 1319

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 5

ER -